Corcept Therapeutics shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $65 to $76.
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics shares rose following Truist Securities' decision to maintain a Buy rating and increase the price target from $65 to $76.
September 30, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics shares increased after Truist Securities reaffirmed its Buy rating and raised the price target from $65 to $76.
The increase in price target and maintained Buy rating by Truist Securities is a positive signal to investors, likely leading to increased buying interest and a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100